Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV ΔNS2 Δ1313 I1314L, Lot RSV#006A, Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age, RSV-Seronegative Infants and Children 6 to 24 Months of Age, and Infants 4 to 6 Months of Age
Brief Summary: Human respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and children around the world. This study will evaluate the safety and immune response to a RSV vaccine in three groups of participants: healthy children who have already had an RSV infection (RSV seropositive), healthy infants and children who have not already had an RSV infection (RSV seronegative), and healthy younger infants who have not been screened for prior RSV infection.


Options:
A: Arm Label: 1 and 2 - Adults; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 3A - Seropositive Children; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 3B - Seropositive Children; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: 4A - Seronegative Infants and Children; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 4B - Seronegative Infants and Children; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: 5A - Seronegative Infants and Children; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 5B - Seronegative Infants and Children; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine; Assigned to Arm(s): 1 and 2 - Adults, 3A - Seropositive Children, 4A - Seronegative Infants and Children, 5A - Seronegative Infants and Children | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 3B - Seropositive Children, 4B - Seronegative Infants and Children, 5B - Seronegative Infants and Children
B: Arm Label: Group 1 Standard; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group 2 Enhanced Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Supplemental training, education and hygiene | Arm Label: Group 3 Chlorhexidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine gluconate, Other: Supplemental training, education and hygiene | Intervention Type: DRUG; Name: Chlorhexidine gluconate; Assigned to Arm(s): Group 3 Chlorhexidine | Intervention Type: OTHER; Name: Supplemental training, education and hygiene; Assigned to Arm(s): Group 2 Enhanced Standard, Group 3 Chlorhexidine
C: Arm Label: MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: MEDI7510 | Arm Label: MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: MEDI7510, Biological: IIV | Arm Label: MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: MEDI7510 | Arm Label: MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4; Type: EXPERIMENTAL; Interventions: Biological: MEDI7510 | Arm Label: Inactivated Influenza Vaccine (IIV); Type: ACTIVE_COMPARATOR; Interventions: Biological: IIV | Intervention Type: BIOLOGICAL; Name: MEDI7510; Assigned to Arm(s): MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1, MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2, MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3, MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4 | Intervention Type: BIOLOGICAL; Name: IIV; Assigned to Arm(s): Inactivated Influenza Vaccine (IIV), MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2
D: Arm Label: Group 1: RSV vaccine; Type: EXPERIMENTAL; Interventions: Biological: RSV ΔNS2 Δ1313 I1314L Vaccine | Arm Label: Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Group 2: RSV vaccine; Type: EXPERIMENTAL; Interventions: Biological: RSV ΔNS2 Δ1313 I1314L Vaccine | Arm Label: Group 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Group 3: RSV vaccine; Type: EXPERIMENTAL; Interventions: Biological: RSV ΔNS2 Δ1313 I1314L Vaccine | Arm Label: Group 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Group 4: RSV vaccine; Type: EXPERIMENTAL; Interventions: Biological: RSV ΔNS2 Δ1313 I1314L Vaccine | Arm Label: Group 4: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: RSV ΔNS2 Δ1313 I1314L Vaccine; Assigned to Arm(s): Group 1: RSV vaccine, Group 2: RSV vaccine, Group 3: RSV vaccine, Group 4: RSV vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Group 1: Placebo, Group 2: Placebo, Group 3: Placebo, Group 4: Placebo

Answer: D